← All companies
ABBV
AbbVie Inc. · Health Care
8 quarters · 75 figures · latest Q3 FY2026 filed 2026-10-30 →
Compared
6 of 8 · select any line below to add or remove it ·
Net revenues
$17.4bn+10.3% Y/YQ3 FY2026
Net earnings
$4.22bn+2144.7% Y/YQ3 FY2026
Diluted earnings per share attributable to AbbVie Inc.
$2.37+2270.0% Y/YQ3 FY2026
Gross margin ratio
75.4%Q3 FY2026
Operating earnings
$6.27bn+229.1% Y/YQ3 FY2026
Acquired IPR&D and milestones
$216m−91.9% Y/YQ3 FY2026
Reported figures
Click any line for its full history. Each figure links to the filing it was read from.
Income statement
24 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Acquired IPR&D and milestonesacquired_iprd_milestones | $1.27bn | $744m | $291m | $216m | −91.9% | −25.8% | |
| Cost of products soldcost_of_products_sold | $4.55bn | $4.22bn | $4.29bn | $4.29bn | −19.2% | −0.1% | |
| As adjusted (non-GAAP) cost of products soldcost_of_products_sold_non_gaap | $2.73bn | $2.46bn | $2.6bn | $2.6bn | +2.1% | +0.1% | |
| Diluted earnings per share attributable to AbbVie Inc.eps_diluted | $1.02 | $0.39 | $2.03 | $2.37 | +2270.0% | +16.7% | |
| Adjusted diluted earnings per shareeps_diluted_non_gaap | $2.71 | $2.65 | $3.65 | $3.82 | +105.4% | +4.7% | |
| Income tax expenseincome_tax_expense | $853m | $342m | $662m | $609m | +15.8% | −8.0% | |
| Interest expense, netinterest_expense_net | $655m | $645m | $679m | $700m | +4.9% | +3.1% | |
| Net earningsnet_income | $1.82bn | $697m | $3.62bn | $4.22bn | +2144.7% | +16.7% | |
| As adjusted (non-GAAP) after-tax earningsnet_income_non_gaap | $4.83bn | $4.71bn | $6.49bn | $6.8bn | +105.5% | +4.7% | |
| Operating earningsoperating_income | $4.54bn | $3.99bn | $6.43bn | $6.27bn | +229.1% | −2.6% | |
| Earnings before income tax expensepretax_income | $2.67bn | $1.04bn | $4.28bn | $4.83bn | +576.3% | +12.9% | |
| As adjusted (non-GAAP) pre-tax earningspretax_income_non_gaap | $5.91bn | $5.57bn | $7.61bn | $7.87bn | +79.6% | +3.3% | |
| Research and developmentrd_expense | $2.58bn | $2.47bn | $2.34bn | $2.57bn | +10.7% | +9.5% | |
| As adjusted (non-GAAP) R&Drd_expense_non_gaap | $2.56bn | $2.27bn | $2.31bn | $2.43bn | +7.5% | +4.8% | |
| Selling, general and administrativesga_expense | $3.9bn | $3.58bn | $3.63bn | $4.09bn | +14.5% | +12.5% | |
| As adjusted (non-GAAP) SG&Asga_expense_non_gaap | $3.71bn | $3.4bn | $3.57bn | $3.69bn | +8.1% | +3.2% | |
| Weighted-average diluted shares outstandingdiluted_shares | — | 1,774 | 1,771 | 1,772 | +0.0% | +0.1% | |
| Net earnings attributable to AbbVie Inc.net_income_attributable | — | $695m | $3.61bn | $4.22bn | +2167.7% | +16.7% | |
| Other expense, netother_expense_net | — | $2.31bn | $1.48bn | $738m | +41.1% | −50.0% | |
| Total operating costs and expensestotal_operating_costs | — | $11.01bn | $10.56bn | $11.14bn | −19.7% | +5.5% | |
| Net revenuestotal_revenue | — | $15bn | $16.99bn | $17.4bn | +10.3% | +2.4% | |
| As adjusted (non-GAAP) income taxesincome_tax_expense_non_gaap | — | $856m | — | — | +17.9% | — | |
| Net revenuesnet_revenue | $16.62bn | — | — | — | +10.0% | — | |
| Adjusted net interest expenseinterest_expense_net_non_gaap | — | — | — | — | $688m | — | — |
Segments
34 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Aestheticsaesthetics_revenue | $1.29bn | $1,186bn | $1,282bn | $1,176bn | — | −8.3% | |
| Botox Cosmeticbotox_cosmetic_revenue | $717m | $668m | $728m | $669m | — | −8.1% | |
| Botox Therapeuticbotox_therapeutic_revenue | $990m | $1.01bn | $1.04bn | $1.08bn | — | +3.6% | |
| Creoncreon_revenue | $385m | $361m | $345m | $361m | — | +4.6% | |
| Elahereelahere_revenue | $182m | $198m | $211m | $224m | — | +6.2% | |
| Epkinlyepkinly_revenue | $81m | $83m | $103m | $108m | — | +4.9% | |
| Humirahumira_revenue | $1.25bn | $688bn | $756bn | $683bn | — | −9.7% | |
| Imbruvicaimbruvica_revenue | $671m | $556m | $532m | $522m | — | −1.9% | |
| Immunologyimmunology_revenue | $8.63bn | $7,290bn | $8,786bn | $9,165bn | — | +4.3% | |
| Juvederm Collectionjuvederm_revenue | $249m | $232m | $245m | $222m | — | −9.4% | |
| Mavyretmavyret_revenue | $324m | $351m | $295m | $265m | — | −10.2% | |
| Neuroscienceneuroscience_revenue | $2.96bn | $2,875bn | $3,228bn | $3,389bn | — | +5.0% | |
| Oncologyoncology_revenue | $1.66bn | $1,631bn | $1,650bn | $1,696bn | — | +2.8% | |
| Other Aestheticsother_aesthetics_revenue | $320m | $286m | $309m | $285m | — | −7.8% | |
| Other Key Productsother_key_products_revenue | $884m | $995m | $935m | $965m | — | +3.2% | |
| Quliptaqulipta_revenue | $288m | $296m | $350m | $398m | — | +13.7% | |
| Rinvoqrinvoq_revenue | $2.37bn | $2,119bn | $2,525bn | $2,706bn | — | +7.2% | |
| Skyriziskyrizi_revenue | $5.01bn | $4,483bn | $5,505bn | $5,776bn | — | +4.9% | |
| Ubrelvyubrelvy_revenue | $339m | $339m | $392m | $449m | — | +14.5% | |
| Venclextavenclexta_revenue | $710m | $770m | $771m | $803m | — | +4.2% | |
| Vraylarvraylar_revenue | $1.02bn | $905bn | $1,071bn | $1,068bn | — | −0.3% | |
| Vyalevvyalev_revenue | $183m | $201m | $256m | $286m | — | +11.7% | |
| Linzesslinzess_revenue | — | $283m | $295m | $339m | — | +14.9% | |
| Other Neuroscienceother_neuroscience_revenue | — | $125m | $117m | $108m | — | −7.7% | |
| Other Oncologyother_oncology_revenue | — | $24m | $33m | $39m | — | +18.2% | |
| Net revenues Int'l.net_revenues_international | — | $4.03bn | — | $4.07bn | — | — | |
| Net revenues U.S.net_revenues_us | — | $10.97bn | — | $13.33bn | — | — | |
| Duodopaduodopa_revenue | — | $92m | — | — | — | — | — |
| Eye Careeye_care_revenue | — | $580m | — | — | — | — | — |
| Int'l. net revenuesinternational_net_revenue | — | $3.82bn | — | — | — | — | — |
| Linzess/Constellalinzess_constella_revenue | — | $175m | — | — | — | — | — |
| Net revenues Int'l.revenue_international | — | — | — | $4.13bn | — | — | — |
| Net revenues U.S.revenue_us | — | — | — | $12.86bn | — | — | — |
| U.S. net revenuesus_net_revenue | — | $12.79bn | — | — | — | — | — |
Operating
1 line
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Unfavorable impact of acquired IPR&D and milestones expense per shareiprd_milestones_eps_impact | $0.71 | — | — | — | −19.3% | — |
Margins
16 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Tax ratetax_rate | 32.0% | 32.9% | 15.5% | 12.6% | −82.9% | −18.7% | |
| Adjusted tax ratetax_rate_non_gaap | 18.3% | 15.4% | 14.7% | 13.6% | −44.5% | −7.5% | |
| Gross margin ratiogross_margin | 72.6% | 71.9% | 74.7% | 75.4% | — | +0.9% | |
| Adjusted gross margin ratiogross_margin_non_gaap | 83.6% | 83.6% | 84.7% | 85.1% | — | +0.5% | |
| Operating margin ratiooperating_margin | 27.3% | 26.6% | 37.9% | 36.0% | — | −5.0% | |
| Adjusted operating margin ratiooperating_margin_non_gaap | 38.3% | 40.8% | 48.3% | 48.7% | — | +0.8% | |
| Acquired IPR&D and milestones expense as percent of net revenuesacquired_iprd_percent_of_revenue | 7.6% | 5.0% | — | 1.2% | — | — | |
| R&D expense as percent of net revenuesrd_percent_of_revenue | 15.5% | 16.5% | — | 14.7% | — | — | |
| Adjusted R&D expense as percent of net revenuesrd_percent_of_revenue_non_gaap | 15.4% | 15.1% | — | 13.9% | — | — | |
| SG&A expense as percent of net revenuessga_percent_of_revenue | 23.4% | 23.9% | — | 23.5% | — | — | |
| Adjusted SG&A expense as percent of net revenuessga_percent_of_revenue_non_gaap | 22.3% | 22.7% | — | 21.2% | — | — | |
| Acquired IPR&D and milestones expense as percent of net revenuesacquired_iprd_pct_revenue | — | — | — | 1.7% | — | — | — |
| R&D expense as percent of net revenuesrd_pct_revenue | — | — | — | 13.8% | — | — | — |
| Adjusted R&D expense as percent of net revenuesrd_pct_revenue_non_gaap | — | — | — | 13.6% | — | — | — |
| SG&A expense as percent of net revenuessga_pct_revenue | — | — | — | 21.4% | — | — | — |
| Adjusted SG&A expense as percent of net revenuessga_pct_revenue_non_gaap | — | — | — | 21.0% | — | — | — |
Guided vs delivered
What the company told the market to expect, against what it then reported. Its own guidance is the only benchmark here — no analyst estimates appear anywhere on this site.
Data from company filings. Not investment advice.